NCT03160781

Brief Summary

The aim of this study was to assess a novel approach to treating severe knee osteoarthritis by targeting synovialmembrane, superficial articular cartilage, synovial fluid, and subchondral bone by combining intra-articular injections and intraosseous infiltrations of platelet rich plasma.This study explored a new strategy consisting of intraosseous infiltrations of platelet rich plasma into the subchondral bone in combination with the conventional intra-articular injection in order to tackle several knee joint tissues simultaneously.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
19

participants targeted

Target at below P25 for phase_2 knee-osteoarthritis

Timeline
Completed

Started Jan 2014

Shorter than P25 for phase_2 knee-osteoarthritis

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 28, 2014

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 10, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 10, 2015

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

May 17, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 19, 2017

Completed
Last Updated

May 19, 2017

Status Verified

May 1, 2017

Enrollment Period

12 months

First QC Date

May 17, 2017

Last Update Submit

May 18, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pain according to KOOS scale at 6 months after treatment

    Pain according to KOOS scale

    6 months

Secondary Outcomes (4)

  • Symptoms according to KOOS scale at 6 months after treatment

    6 months

  • Function according to KOOS scale at 6 months after treatment

    6 months

  • Sport Activity according to KOOS scale at 6 months after treatment

    6 months

  • QoL according to KOOS scale at 6 months after treatment

    6 months

Study Arms (1)

Platelet Rich Plasma

EXPERIMENTAL

Combination of Intraarticular and Intraosseous Administraion of Platelet Rich Plasma

Biological: Platelet Rich Plasma

Interventions

Combination of Intraosseous and Intraarticular Infiltration of Platelet Rich Plasma

Platelet Rich Plasma

Eligibility Criteria

Age40 Years - 77 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients of both sexes aged 40 to 77 years.
  • Predominant internal tibiofemoral knee osteoarthritis.
  • Joint pain above 2.5 VAS points.
  • Radiographic severity degrees 3 and 4 according to Ahlbäck scale.
  • Values of body mass index between 20 and 33.
  • Possibility for observation during the follow-up period.

You may not qualify if:

  • Bilateral knee osteoarthritis which requires infiltration in both knees.
  • Values of body mass index \> 33.
  • Polyarticular disease diagnosed.
  • Severe mechanical deformity (diaphyseal varus of 4∘ and valgus of 16∘).
  • Arthroscopy in the last year prior to treatment.
  • Intra-articular infiltration of hyaluronic acid in the past 6 months.
  • Systemic autoimmune rheumatic disease (connective tissue diseases and systemic necrotizing vasculitis).
  • Poorly controlled diabetes mellitus (glycosylated hemoglobin above 9%).
  • Blood disorders (thrombopathy, thrombocytopenia, and anemia with Hb \< 9).
  • Undergoing immunosuppressive therapy and/or warfarin.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Osteoarthritis, Knee

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 17, 2017

First Posted

May 19, 2017

Study Start

January 28, 2014

Primary Completion

January 10, 2015

Study Completion

January 10, 2015

Last Updated

May 19, 2017

Record last verified: 2017-05

Data Sharing

IPD Sharing
Will not share